[go: up one dir, main page]

CL2008002786A1 - Torta farmceuticamente aceptable, formada por liofilizacion, que comprende: n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il]-etil]-amino]-metil]-fenil]-2e-2-propenamida o una sal, un regulador de ph seleciondo de lactato o acidop lactico, fodfato o acido fosforico o una combinacion y un agente de volumen; proceso de elaboracion. - Google Patents

Torta farmceuticamente aceptable, formada por liofilizacion, que comprende: n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il]-etil]-amino]-metil]-fenil]-2e-2-propenamida o una sal, un regulador de ph seleciondo de lactato o acidop lactico, fodfato o acido fosforico o una combinacion y un agente de volumen; proceso de elaboracion.

Info

Publication number
CL2008002786A1
CL2008002786A1 CL2008002786A CL2008002786A CL2008002786A1 CL 2008002786 A1 CL2008002786 A1 CL 2008002786A1 CL 2008002786 A CL2008002786 A CL 2008002786A CL 2008002786 A CL2008002786 A CL 2008002786A CL 2008002786 A1 CL2008002786 A1 CL 2008002786A1
Authority
CL
Chile
Prior art keywords
methyl
propenamide
indol
hydroxy
phenyl
Prior art date
Application number
CL2008002786A
Other languages
English (en)
Inventor
Thitiwan Buranachokpaisan
Wenlei Jiang
Jiahao Zhu
Wei-Qin Tong
Joseph Lawrence Zielinski
Hans-Peter Zobel
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40005335&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2008002786(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2008002786A1 publication Critical patent/CL2008002786A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Composición farmacéutica que comprende n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)-etil]-amino]metil]fenil]-2e-2-propenamida o una sal farmacéuticamente aceptable, un buffer y un agente de volumen.
CL2008002786A 2007-09-20 2008-09-17 Torta farmceuticamente aceptable, formada por liofilizacion, que comprende: n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il]-etil]-amino]-metil]-fenil]-2e-2-propenamida o una sal, un regulador de ph seleciondo de lactato o acidop lactico, fodfato o acido fosforico o una combinacion y un agente de volumen; proceso de elaboracion. CL2008002786A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US97383007P 2007-09-20 2007-09-20

Publications (1)

Publication Number Publication Date
CL2008002786A1 true CL2008002786A1 (es) 2009-05-15

Family

ID=40005335

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008002786A CL2008002786A1 (es) 2007-09-20 2008-09-17 Torta farmceuticamente aceptable, formada por liofilizacion, que comprende: n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il]-etil]-amino]-metil]-fenil]-2e-2-propenamida o una sal, un regulador de ph seleciondo de lactato o acidop lactico, fodfato o acido fosforico o una combinacion y un agente de volumen; proceso de elaboracion.

Country Status (20)

Country Link
US (1) US20100331387A1 (es)
EP (1) EP2205222A1 (es)
JP (1) JP2010540445A (es)
KR (1) KR20100059887A (es)
CN (1) CN101801345A (es)
AR (1) AR068822A1 (es)
AU (1) AU2008302273A1 (es)
BR (1) BRPI0817118A2 (es)
CA (1) CA2696914A1 (es)
CL (1) CL2008002786A1 (es)
CO (1) CO6270207A2 (es)
EC (1) ECSP10010039A (es)
GT (1) GT201000062A (es)
MA (1) MA31744B1 (es)
MX (1) MX2010002970A (es)
PE (1) PE20090706A1 (es)
RU (1) RU2010115262A (es)
TN (1) TN2010000097A1 (es)
TW (1) TW200930416A (es)
WO (1) WO2009039226A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3347055T3 (pl) * 2016-03-31 2019-11-29 Midatech Ltd Addukt cyklodekstryny-panobinostatu

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020354A1 (es) * 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
US7250514B1 (en) * 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
HRP20060073B1 (hr) * 2003-07-23 2014-03-14 Bayer Healthcare Llc Fluoro supstituirana omega-karboksiaril difenil urea za lijeäśenje i prevenciju bolesti i stanja
JP2007501775A (ja) * 2003-08-07 2007-02-01 ノバルティス アクチエンゲゼルシャフト 免疫抑制剤としてのヒストンデアセチラーゼ阻害剤
PE20060664A1 (es) * 2004-09-15 2006-08-04 Novartis Ag Amidas biciclicas como inhibidores de cinasa
US20060128660A1 (en) * 2004-12-10 2006-06-15 Wisconsin Alumni Research Foundation FK228 analogs and methods of making and using the same
US7604939B2 (en) * 2005-03-01 2009-10-20 The Regents Of The University Of Michigan Methods of identifying active BRM expression-promoting HDAC inhibitors
EP2117598A2 (en) * 2007-01-10 2009-11-18 Novartis AG Formulations of deacetylase inhibitors
EP2491923A3 (en) * 2007-02-15 2012-12-26 Novartis AG Combinations of therapeutic agents for treating cancer

Also Published As

Publication number Publication date
KR20100059887A (ko) 2010-06-04
RU2010115262A (ru) 2011-10-27
MA31744B1 (fr) 2010-10-01
TW200930416A (en) 2009-07-16
EP2205222A1 (en) 2010-07-14
BRPI0817118A2 (pt) 2019-09-24
CO6270207A2 (es) 2011-04-20
AU2008302273A1 (en) 2009-03-26
CN101801345A (zh) 2010-08-11
US20100331387A1 (en) 2010-12-30
WO2009039226A1 (en) 2009-03-26
GT201000062A (es) 2012-03-30
CA2696914A1 (en) 2009-03-26
PE20090706A1 (es) 2009-07-15
ECSP10010039A (es) 2010-04-30
MX2010002970A (es) 2010-04-01
TN2010000097A1 (en) 2011-09-26
JP2010540445A (ja) 2010-12-24
AR068822A1 (es) 2009-12-09

Similar Documents

Publication Publication Date Title
MX2009008584A (es) Combinacion de lbh589 con otros agentes terapeuticos para el tratamiento de cancer.
AR061298A1 (es) Sales de n-hidroxi -3- [4- [ [ [2- (2-metil-1h-indol-3-il) etil] amino] metil] fenil] -2e-2- propenamida.composciones farmaceuticas.
NZ598839A (en) Stabilized liquid and lyophilized adamts13 formulations
HRP20040807B1 (hr) Oblik etil estera 3-[(2-{[4-(heksiloksikarbonilamino-imino-metil)-fenilamino]-metil}-1-metil-1h-benzimidazol-5-karbonil)-piridin-2-il-amino]-propionske kiseline i njegovih soli za oralnu aplikaciju
IL198979A (en) Enzyme inhibitors diacylglycerol o-acetyltransferase type 1
PE20121732A1 (es) Derivados de ciclohexano espiro-condensado como inhibidores de hsl utiles en el tratamiento de la diabetes
NO20084418L (no) Azolopyridin-3-on derivater som inhibitorer av endoteliallipase
SG195141A1 (en) Combination of panobinostat and ruxolitinib in the treatment of cancer suchas a myeloproliferative neoplasm
EA201070598A1 (ru) Терапевтическое применение соединений, обладающих комбинированной активностью в отношении sert, 5-htи 5-ht
EA201101671A1 (ru) Замещенные производные аминопропионовой кислоты в качестве ингибиторов неприлизина
NO20082834L (no) 2-(fenyl eller heterosyklisk)-1H-fenantro[9,10-D]imidazoler som MPGES-1-inhibitorer
MX2013005533A (es) Derivados de acido amino-bisfenil-pentanoico sustituidos como inhibidores de nep.
ATE551328T1 (de) Neuartige 5-substituierte hydantoine
IN2012DN03391A (es)
CO6612204A2 (es) Nuevas composiciones de 1-(2(2.4 dimetil-fenilsulfanil)- fenil) piperazina
JO3099B1 (ar) طريقة تصنيع املاح من n- هيدروكسي -3- [4-[[[2-(2-مثيل-h 1-اندول -3-يل)ايثيل]امينو]مثيل]فنيل]-e-2-2بروبان اميد
NO20083535L (no) Alfa-krystallinsk form av argininsaltet til perindopril, en prosess for dets fremstilling og farmasoytiske sammensetninger inneholdende dette
NZ596820A (en) Trans-4-[[(5s)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl] (2-methyl-2h-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1h-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid
AU2009273259A1 (en) Sphingosine 1 phosphate receptor modulators and their use to treat muscle inflammation
CL2008002786A1 (es) Torta farmceuticamente aceptable, formada por liofilizacion, que comprende: n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il]-etil]-amino]-metil]-fenil]-2e-2-propenamida o una sal, un regulador de ph seleciondo de lactato o acidop lactico, fodfato o acido fosforico o una combinacion y un agente de volumen; proceso de elaboracion.
CR20130181A (es) UNA COMPOSICIÓN QUE COMPRENDE 2-metilpropanotioato de S-[2-([[1-(2-etilbutil)ciclohexil]-carbonil]amino)fenilo] Y CROSCARMELOSA SODICA
CL2011000187A1 (es) Preparacion farmaceutica que comprende (5-metil-2-oxo-1,3-dioxol-4il)metil 2-etoxi-1-{[2,{5-oxo-4,5-dihidro-1,2,4-oxadiazol-3-il)bifenil4il]metil}-1h-benzimidazol-7-carboxilato, un agente de control de ph entre 2 y 5 y un diuretico; metodo para estabilizar; metodo para mejorar disolucion, util en enfermedades inducidas por angiotensina ii.
UA94251C2 (ru) Индолпроизводная соль лимонной кислоты и ее фармацевтическое применение
PE20090445A1 (es) Inhibidores de produccion de beta amiloide
WO2010024702A3 (en) Pharmaceutical composition for the treatment of periodontal diseases